← All trials
NCT00022191
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2001
- Primary completion
- Jun 1, 2004
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 608
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- European Organisation for Research and Treatment of CancerLead sponsor
- German Association of Urologic OncologyCollaborator
- University of MontpellierStudy chair
- Universitaetsklinikum Schleswig-HolsteinStudy chair
- University of MichiganStudy chair
- University of Western AustraliaStudy chair
- Medical University of ViennaStudy chair
- National Cancer Institute (NCI)Collaborator
- Groupe D'Etude des Tumeurs Uro-GenitalesCollaborator
- Central European Cooperative Oncology GroupCollaborator
- Southwest Oncology GroupCollaborator
- Spanish Oncology Genito-Urinary GroupCollaborator
- Medical Research CouncilCollaborator
- University of LondonCollaborator
- Canadian Cancer Trials GroupCollaborator
- University of TorontoStudy chair
- Universidad Autonoma de BarcelonaStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.